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ABSTRACT  
In this work, we formulated a mathematical model to study the 
interaction between HIV/AIDS and Cluster of Differentiation 4 
cells (CD4+T), incorporating the roles of Cytotoxic T- lymphocytes 
(CTLs) cells and antiretroviral therapy. The proliferation of CD4+T 
cells was considered to follow the logistic growth pattern. The 
presence of HIV in the CD4+T cells stimulates the recruitment of 
CD4+T and CTL cells. The recruitment of uninfected CD4+T and 
CTL immune cells fall purely as an exponential function of time in 
the presence of HIV. The basic reproduction number  0R was 
obtained using the next generation matrix method. We adopted 
the Jacobian stability criterion and the Lyaponuv second method 
of stability to establish the local and global stabilities of the 
equilibrium states and show that HIV can be eliminated from 
CD4+T cells when
0 1R   but will continue to persist within 
CD4+T cells when 0 1R  . Early medication therapy was 
observed to reduce viral load and increase the number of CTL 
cells, while CD4+T cells is kept above the AIDS bar. A high initial 
viral load was noticed to induce rapid decline in the number of 
CD4+T cells. To keep a healthy system, we recommended that 
the CTL and uninfected CD4+T cells population should be 
maintained by reducing viral load through early medication 
therapy and cloning of CTL cells within infected human, which 
fights and kills infected cells. 
 
Keywords: Basic Reproduction Number (
0R ), Virus-free 
Equilibrium (VFE), Endemic Equilibrium (EE), Locally 




One of the ever-known deadly diseases which has undoubtedly 
claimed millions of lives is Acquired Immune Deficiency 
Syndrome (AIDS). AIDS is the disease that results from the 
breakdown of the immune system, occasioned by the invasion of 
a virus called Human Immunodeficiency Virus (HIV). This disease 
kills and damages cells of the human body’s immune system. It 
gradually destroys its ability to fight against other infections and 
diseases (Allali, Harroudi & Torres, 2018).  
AIDS is one of the leading epidemics in the world.  The first 
patient was diagnosed in 1981 (Bushnaq, et al., 2018). As at 
2016, about 36.7 million people were living with HIV/AIDS 
globally, out of which only 20.9 million people were accessing 
antiretroviral therapy. 1.8 million people became newly infected. 
In sum, about 78 million people have been infected with HIV since 
the discovery of the epidemic and about 35 million people have 
died from HIV/AIDS related diseases. Figure of newly infected 
persons stand at 2.1 million. In Nigeria, about 3.5 million persons 
are reported to be carrying the deadly virus. Number of death 
recorded due to HIV/AIDS is given as 180,000 persons, with a 
prevalent rate of 3.1% among adults, aged 15 and above 
(UNAIDS, 2016). 
HIV/AIDS can be contracted through unprotected sex with an 
infected person, sharing of needle with an infected person, breast 
milk of an infected person and blood transfusion from an infected 
person (UNICEF, 2003).  
It is important to study the pattern of HIV progression in the body. 
There are three stages of HIV/AIDS infection. They are the 
Primary Phase, Asymptomatic Phase and AIDS Phase. During 
the Primary Phase, an individual develop flu-like symptoms 
between 2 – 4 weeks after HIV infection (Miller et al., 2018). The 
symptoms could include fever, swollen glands, sore throat, rush, 
muscle and headache. This stage is sometimes referred to as 
Acute Retroviral Syndrome (ARS). During this stage, large 
amounts of virus are replicated in the cells of the body. The target 
cells are the Cluster of Differentiation 4 (CD4+T) cells. As the 
activities of the virus increases, the CD4+T cells would eventually 
decline in numbers. The levels of HIV in the body blood stream 
are very high at this stage thereby there is a high risk of 
transmitting the virus to others. The Asymptomatic Phase of HIV 
infection is that period when HIV is living and replicating at a very 
low rate without manifesting symptoms. This stage is also referred 
to as chronic HIV infection phase. The final stage is the AIDS 
Phase. At this point, the HIV has badly damaged the immune 
system thereby making the infected individual vulnerable to 
opportunistic infections. This is signaled by the decline in the 
number of CD4+T cells. Once the CD4+T cells count falls below 
200 cells/mm3 of blood, an individual is considered to have 
progressed to AIDS stage (WHO, 2007; Mita, 2013).  
The process of virus replication in the immune cells increases 
rapidly with time in infected individuals that are not placed on 
medication therapy. The introduction of medications therapy in 
treating HIV/AIDS infection would definitely suppress or slow 
down the rate of virus activities in the immune system. Current 
research shows that more than 16 antiretroviral drugs have been 
developed and approved by World Health Organization (WHO), 
United Nations Children Fund (UNICEF) and Joint United Nations 
Programmes for AIDS (UNAIDS), the most common being 
Protease Inhibitors and RT Inhibitors. The former functions by 
meddling with the process of virus replication so that virus would 
only replicate themselves but prevented from invading the host 
cell. The later on the other hand “deceives” the reverse 
transcriptase (enzyme which produce the viral particles) to create 
false DNA that will not replicate HIV. The most effective 
medication therapy is called Highly Active Antiretroviral Therapy 
(HAART). It combines two or more antiretroviral medications to 
fight HIV/AIDS. The main function of HAART is to decrease viral 























HIV/AIDS-Invivo Model With the Roles of CTL Immune Cells and Antiretroviral 
Theraphy 
 
recover some strength. 
 
LITERATURE REVIEW 
Biological processes are complex to study. However, modeling of 
biological processes such as epidemiology and virology has 
paved ways to scientist to undertake research using mathematical 
tools to study the components and parameters of such processes. 
In line with this, several authors have written on the progression 
and diffusion of HIV infection in human immune system. 
Roy & Chatterjee (2010), built a mathematical model of HIV-1 
infection to CD4+T cells and included a combination of inhibitor-
drugs (lamivudine and zidovudine) as medication therapy. This is 
in variant with the model formulated by Srivastava et al. (2009), 
which incorporated only a single drug. They had observed from 
available clinical results that patients infected with type-1 HIV and 
treated with these inhibitor-drugs show a 10 to 25% growth in the 
healthy CD4+T cells count. In developing their model, they 
considered ( )x t and ( )y t to be uninfected and infected cells 
respectively at time t . Uninfected CD4+T cells are produced at a 
constant rate and are removed from the system through the 
natural death rate d  . It was assumed that at the steady state, 
the free virus population is proportional to the virus-producing 
CD4+T cells which are already infected. The process of infection 
of infected CD4+T cells obeys the law of mass action. This 
necessarily implies that the number of new infection at steady 
state is proportional to  ( ) ( )x t y t . The production rate of new 
immunocompetent T cells produced by lymphatic system is taken 
to be   and it does not depend on the number of T cells. It was 
also assumed that T cells may be produced by the proliferation of 
existing T cells and its production is governed by the logistic 
growth law. That is, T cells cannot increase infinitely. Hence, the 
proliferation of T cells was represented in a logistic manner where
p , the maximum proliferation rate is constant and it proliferates 
to a maximum given by mT  (the point at which T cell population 
cannot exceed). In line with these assumptions, the following 
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      (2) 
where a  is the death rate of infected CD4+T cells. 
 
The rate of replication of virus declines whenever a HIV-1 infected 
individual is treated with drugs. This effect was incorporated in 
their model by reducing the numerical value of the parameter  . 
Another variable z  was included to address the long term 
immune of the model. z is taken to be the density of CTL 
responses against infected cells. In sum, Roy & Chartejee (2010), 









     
 








      (5) 
where k is the killing rate of virus producing cells by CTL, s  is 
the rate of stimulation (recruitment) of CTL and b  is the mortality 
rate of CTL. The result of their analysis and stimulation reveals 
the following: 
(i) the proliferation rate is always greater than the death 
rate of uninfected cells, which implies that the disease 
free system cannot be obtained, 
(ii) if the proliferation rate increases, then the uninfected 
cell increases fast but the infected and CTL population 
increases slowly, 
(iii) if the force of infection  , increases, then the 
numerical value of infected cell and CTL population 
decreases.  
They concluded that the system competes with the killing rate of 
infected T-cells as well as stimulation rate of CTL. While the 
modelers included the effect of CTL immune in the model, the 
equation did not consider viral particles as a population to study.    
Parumasur & Willie (2008), carried out a research to analyse 
model parameters in HIV/AIDS equation models. Their model 
comprises four compartments, namely: virus population ( )v , 
uninfected target cells ( )x , infected cells ( )y  and immune 
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where a  is the rate of virus reproduction, b  is the rate of death 
of viruses, c is the reproduction of uninfected cells, d  is the 
death rate of uninfected cells,   is the multiplying constant of 
being infected, g is the reproduction rate of cells z , h  is the 
death rate of cells z  and  is the multiplying constant to the 
elimination of infected cells. The model will be more robust if drug 
therapy was included. 
The study of HIV/AIDS infection dynamics came with diverse 
challenges. No single models have been developed thus far, so 
exhaustive enough to address all the multifaceted dimensions of 
HIV/AIDS infections.  
We proposed a set of equations that considers the following 
factors in a single deterministic model: 
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(i) combinatory effects of CTL immune cells and drug therapy 
on HIV infection, 
(ii) both the CD4+ cells and the CTL immune cells have two 
sources; they proliferate and are produced from the bone 
marrow and from other immune-producing hormones 
respectively (Olaniyi, et al., 2013),  
(iii) no cell type in the  human body continues to proliferate 
unboundedly. Hence the CD4+ cells was considered to 
follow a logistic growth pattern, and  
(iv) the production of uninfected CD4+ cells and CTL immune 
cells fall purely as an exponential function of time in the 
presence of HIV.  
(v) the activities of CTL immune cells in the system can reduce 
infectivity but cannot eliminate free viruses in the system, 
(vi) the invasion of HIV in the system triggers the proliferation of 
CTL immune cells but causes a decline in the production of 
CD4+ cells and CTL immune cells (Allali, Harroudi & Torres, 
2018) and  
(vii) drug therapy blocks new infections and slow down the rate 
of virus recruitment but cannot eliminate HIV. 
Uninfected CD4+T cells proliferates and are recruited according to 
a logistic growth term at the rates
1 and 1s  respectively, with 
natural death rate
1 . We noted that the proliferation and 
recruitment of CD4+T cells cannot continue to increase 
unboundedly, hence, the introduction of the logistic growth terms 
with CD4+T cells size 
maxT  
as the carrying capacity. 
 
 
Fig. 1: Schematic Diagram of HIV in-vivo Model 
 
The term
kVe is a reduction factor that accounts for decrease in 
the number of healthy CD4+T cells and CTL immune cells that will 
be produced once an antigen is introduced into the system, where 
0, 1, 2, 3, 4,...k  , takes on the values of t . We assumed 
that the recruitment of uninfected CD4+T cells and CTL immune 
cells fall purely as an exponential function of time. This is in line 
with the work of Wodarz & Nowak (2002).    
In the case that antiretroviral therapy are not administered, 
uninfected CD4+T cells become infected by free virus at the rate
 . Infected CD4+T cells die naturally at the rate 2  as well as 
due to CTL immune cells at the rate .  
Free viruses are produced whenever infected CD4+T cells burst. 
This is represented by the term 
2NI , where N is number of 
new viruses. Virus density decreases due to natural death at the 
rate
4 . We assume that a CTL immune cells proliferate and are 
recruited in response to an antigen at the rate 
2  and 2s  
respectively. The CTL immune cells die naturally at the rate
3   
The model  is described by a system of ordinary differential 
equations given in (10) – (13).  
 















        (11) 
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kVdC s e CI C
dt





        (13) 
Since the model is dealing with populations, all the variables and 
parameters of the model are positive with the natural death rates 
positive, i.e.  1 2 3 4, , , 0     , thus considering the region
  where: 
  4, , , : 0, 0, 0, 0U I C V U I C V     R   (14)  
It can be established that all solutions of the system starting in 
  remain in  for all 0t    . In this region, the usual 
existence, uniqueness and continuation of results hold for the 
system. 
 
Existence of Virus-free Equilibrium, 
0E   
The rate of change of the systems in (10) – (13) is equal to zero 
at the point of equilibrium. That is  
0   
dU dI dC dV
dt dt dt dt
   (15) 
At any arbitrary equilibrium point, let 
 
   * * * *, , , , , ,U I C V U I C V   (16) 
Hence we have  
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  (17) 
2 0VU CI I        (18) 
2 2 3 0
kVs e CI C        (19) 
2 4 0NI VU V        (20) 
We solved equations (17) – (20) simultaneously to obtain our 
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   (21) 
where  




2 1 max 1 1 max 1 1 max4U T s T s T       (23) 
 
Basic Reproduction Number, 
0R  
Yuan (2010), elucidated a method for obtaining
0R . The method 
is known as the next generation matrix method. This technique 
was adopted to obtain the effective reproduction number of the 
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  (26) 
Therefore,  









   

 
   (27) 
 
Local Stability of Virus-free Equilibrium 
Theorem 1: The virus-free equilibrium of the model equations 
(10) – (13) is locally asymptotically stable if 
0 1R  .  
 
Proof: The Jacobian stability technique was employed in 
determining the local stability of the system. The Jacobian matrix 
obtained by operating on equations (10) – (13), at virus-free 
equilibrium, 






























 01 1 1 1 max 1 max2J s U T T        (29) 
 02 1 1J s U      (30) 
 0 03 1 max maxJ ks T U T U        (31) 
 04 2J C       (32)  
 05 4J U       (33) 
 
The characteristic equation of the Jacobian matrix in equation 






























So that the eigenvalues are 
 
 01 1 1 1 max 1 max2 0s U T T           (35) 
 02 2 0C          (36) 
3 3 0         (37) 











  (38) 
For 4 to be negative,  











  (39) 
 
Simplifying equation (39) gives 
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
 
   (40) 
 
That is, 
0 1R        (41) 
It is logical therefore to say that 4 0   if 0 1R  . It follows that 
the virus-free equilibrium,
0E , of the model equations (10) – (13) 
is locally asymptotically stable if
0 1R  .  By implication, HI virus 
can be removed from the CD4+T cells if 
0 1R  .  
 
Global Stability of Virus-free Equilibrium, 
0E  
 
Theorem 2: The VFE of the system (10) – (13) is globally 
asymptotically stable in   if
0 1R  .  
Proof: The Lyaponuv’s second method for stability theorem was 
adopted to establish the global stability of the system (Lyaponuv, 
1892).  
 
Consider the Lyapunov function in equation (42):  
 2 2L NI C V         (42) 
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Differentiating (42) gives 
 ' ' '2 2L NI C V         (43)   
Substituting the values of 
'I  and 
'V into (43) yield 
 




L N VU CI I
C NI VU V
   
   
  
   
  (44) 








L C U V
C U
 
   
   
 
    
   
  (45)   
 
At any arbitrary point at equilibrium state,
0U U  and 0C C . 









L C U V
C U
 
   
   
 
    
  
 
  (46)  
 
Thus,  
   ' 22 4 0 1L C U V R            (47) 
 From (42), it is obvious that for 0I V  , 0L   and for 
0I V  , 0L  . Furthermore, from (47), it can be shown 
that 
' 0L   if 0 1R   and 0V  . 
' 0L   is true when 
0 1R  . If 0 1R  , then 
' 0L   except when 0V  . Hence, 
by Lyapunov’s second method for stability theorem, the virus-free 
equilibrium state is proved to be globally asymptotically stable. 
 
RESULTS AND DISCUSSION 
The infection rate  , is reduced by  1 b   when 
antiretroviral drugs are administered. 0 1b   
is taking to be 
the potency of the drugs in blocking the ability of HIV from actively 
infecting the healthy CD4+T cells. Due to the application of 
antiretroviral therapy, the recruitment of free viruses is reduced by 
 1 p  , where 0 1p   is the potency of the drugs in 
slowing down the rate at which free viruses are recruited.   is 
the level of adherence to the usage of drugs. The potency of the 
drug when medication plans are followed is estimated at 95% 
(UNAIDS, 2015).  
Variables and Parameters Value  
Variables and parameters of HIV/AIDS models are usually 
estimated based on HIV/AIDS available data. The values used in 
this research work are presented in Table 1. 
 
Table 1: Variables and parameters value  
Symbols Values Source 
(0)U  1000 mm-3 Culshaw & Ruan (2000) 
(0)I  0 Culshaw & Ruan (2000) 
(0)V  Varies  Assumed 
(0)C  200000 mm-3 Assumed 
maxT  1500 mm
-3 Roy & Chartterjee 
(2010) 
N  Varies Assumed 
,b b   0.95 UNAIDS (2015) 
  Varies Assumed 
1s  10 mm-
3 day-1 Roy & Chartterjee 
(2010) 
2s  0.2 mm-
3 day-1 Roy & Chartterjee 
(2010) 
1  0.03 day
-1 Culshaw & Ruan (2000) 
2  0.03 day
-1 Culshaw & Ruan (2000) 
1  0.02 day
-1 Culshaw & Ruan (2000) 
2  0.24 day
-1 Culshaw & Ruan (2000) 
3  0.02 day
-1 Culshaw & Ruan (2000) 
4  0.2 day
-1 Culshaw & Ruan (2000) 
  0.000024 mm3 
day-1 
Culshaw & Ruan (2000) 






Fig. 2: Plot of uninfected CD4+T cells versus time at virus-free 
equilibrium state, corresponding to (0) 0V   and 0N  . 
 
Fig. 2 shows the behavior of the uninfected CD4+T cells at virus-
free equilibrium. This is the state at which the entire CD4+T cells 
population is free from HIV. Decline in the number of uninfected 
cells is due to natural death. The lower limit is greater than 
700cell/mm3 CD4+T cells count for all values of 0t  , which is 
far above the AIDS upper bound.  
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Fig. 3: Plot of uninfected CD4+T cells versus time at different level 
of patients’ adherance to antiretroviral therapy (drug 
usage), keeping the initial volume of virus at minimal 
level of (0) 10V   and 500N  . 
 
We observed a fast downward movement of healthy CD4+T cells 
when the level of drug usage was 0%. The population of 
uninfected CD4+T cells thus fall below 200cell/mm3 within the first 
two years of viral infection, a situation that fast track the 
progression of HIV to AIDS stage. At 25% and 50% levels of drug 
usage, the CD4+T cells maintained a value just above 200mm-3, 
but clearly, the trend shows a downward movement. As viral load 
increases, the count will definitely go below 200cell/mm3. The 
best fit was obtained when drug usage was 95%. Though, there 
was a liitle drop from the number of healthy CD+T cells from 
1000cell/mm3 to 800cell/mm3, we observe no further decline. This 
implies that at 95% level of usage of antiretroviral therapy, 
patients who are HIV-positive can keep their CD4+T cells count 
above 200cell/mm3, thereby not resulting into AIDS. Life 
expentancy for infected persons in this category is estimated at 
between 20 – 50 years (Klatt, 2014).  
 
 Fig. 4: Plot os the behaviour of uninfected CD4+T cells with 
respect to time, at different level of patient’s adherance to drug 
usage with (0) 100V   and 2000N  . 
 
In this case, the initial volume of viral particle introduced into the 
system was inreased from 10 to 100, thereby causing more 
viruses to be produced by the process of lysing of infected CD4+T 
cells. Thus, with a larger volume of viral particles in the system, 
the decrease in the number of heathy CD4+T cells was more rapid 
than the scene in Fig. 3. At 0%, 25% and 50% level of adherence 
to drug usage, within the periods less than 2 years, the infection 
has progressed to AIDS stage except at 95% where the infection 
is still in check and above AIDS line indicator. 
 
 
Fig. 5:  Plot of the behaviour of uninfected CD4+T cells after a 
delay of 1 year before treatments begin. (0) 10V  ,
500N  , at different level of adeherence to drug usage 
by patient. 
From Fig. 5, it can be observed that due to delay in starting 
treatments, the number of healthy CD4+T cells have declined 
below 450cell/mm3 and just above 250cell/mm3 from the onset of 
treatments. Except treaments is sustained at 95% from this point, 
AIDS will result in less than 1 year (at 25% drug usage). At 50% 
drug usage, the patient may still be able to keep a CD4+T cells 
count just above the bar for another 2 years, owing to the low 
initial number of viral particles in the system, and the minimal 
number of virus produced by lysing of infected CD4+T cells. 
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Fig. 6:  Plot os the behaviour of uninfected CD4+T cells after a 
delay of 1 year after infection. (0) 200V  , 5000N  .  
Fig. 6 is a case where the initial volume of viral particles 
introduced into the system is large. Invariably, the amount of 
viruses that will be produced when infected CD4+T cells burst will 
be higher than what we have in Fig. 5. The high viral particles in 
the system resulted into the decrease of healthy CD4+T cells 
below 200cell/mm3. Hence, before HIV was diagnosed in this 
case, AIDS have resulted. This is typical of infected individuals 
who do not receive any form of treatment. Death usually occur 
within a year after the individual progresses from HIV to AIDS 
(Klatt, 2014).  
 
 
Fig. 7:  Plot of viral load and uninfected CD4+T cells population 
versus time in the absence of antiretroviral therapy. 
(0) 100V   , 5000N  . 
In Fig.7, the activities of HIV is at the peak in the system, hence 
the decrease in the number of healthy CD4+T cells. It is observed 
that treatment is absence in this sytem. Progression from HIV 
stage to AIDS stage will be faster. 
 
 
Fig. 8:  Plot of viral load and uninfected CD4+T cells population 
versus time in the presence of antiretroviral therapy. 
(0) 10V   , 100N   and 0.95  . 
 
It is observed from Fig. 8 that viral load is kept at the base once 
drug usage level is 95% and begins early. This demonstrates the 
role of early treatment in suppressing the activities of the virus. 
The abundance of CD4+T cells in the system will make HIV to be 
undetectable when clinical tests are carried out (Perelson & 




Fig. 9:  Plot of uninfected CD4+T cells and viral load versus 
time at the point when the CTL immune cells term was 
deactivated in the model equation (i.e. when (0) 0C  ). 
(0) 100V  , 2000N  . 
 
Fig. 9 displays the role of CTL immune cells in regulating viral 
load. The idea here was that of deactivating the CTL immune 
cells term in the model equation, a situation which is not feasible 
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in the immune system. However this picture provides some 
mathematical insight into the role of CTL immune cells. Obviously, 
as (0) 0C  , ( ) 10, 000V t 
 
and ( ) 200U t   at 15t 
days. This is logical. The implication of this assertion is that, for 
the system to remain healthy, the population of CTL immune cells 
must be kept at a value greater than zero and the population of 
uninfected CD4+T cells must be kept above 200cell/mm3.  
 
Conclusion  
In this work, we proposed and analysed a model of HIV/AIDS in-
vivo with the roles of CTL immune cells and antiretroviral therapy. 
The model comprises four compartments, namely: uninfected 
CD4+T cells ( ),U infected CD4+ T cells ( ),I  density of free 
virus ( ),V  and CTLs ( ).C
 
Results from the projections indicate 
that the introduction of antiretroviral therapy at the early stage of 
infection leads to a decrease in viral growth and increase in the 
population of healthy CD4+T cells. This agrees with conventional 
results (Wodarz & Nowak, 2002). Sustenance of such drugs 
should be more than one year (Perelson et al., 1993). 
Deactivating the role of CTL immune cells in the model equation 
resulted in a drastic increase in viral load and a fast progression 
from HIV stage to AIDS stage. On the other hand, increasing the 
population of CTL immune cells keeps the viral load in check. 
This suggests that, with the multiplication of healthy CTL immune 
cells in the system, viral growth will be minimal. This scenario was 
also observed by Roy & Chatterjee (2010).   
The absence of antiretroviral therapy or lack of adherence to 
medication plans will lead to a rise in virus replication within the 
host. Thus, there will be exponential fall in the number of CD4+T 
cells and CTL immune cells. This is another scenario where there 
will be a fast progression from HIV stage to AIDS stage. With the 
introduction of small initial population of free virus in the system, 
the probability of increase of virus is kept at a minimal level. On 
the contrary, a larger initial population size of virus increases the 
chance of free virus infecting more healthy CD4+T cells. Hence, 
any measure that will keep the initial viral population to the barest 
minimum will be a good one.  
 
The study revealed that a large volume of CTL immune cells will 
slow down viral load, and kill infected CD4+T cells, hence, more 
effort should be geared towards producing CTL immune cells 
booster. The medical scientist should also intensify effort in 
discovering methods of cloning CTL immune cells in infected 
humans. This will aid in increasing the number of the CTL 
immune cells. Free and regular HIV/AIDS screening exercise, 
coupled with HIV/AIDS awareness, should be encouraged and 
sponsored by the Nigerian Government, to enable early detection 
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